RecruitingAtopic Dermatitis
Dupilumab De-escalation in Pediatric Atopic Dermatitis
Eligible age
1–17 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a pilot investigator-blinded, randomized clinical trial to assess the feasibility of dupilumab treatment discontinuation or dose-reduction in children aged 1-17 years who have achieved sustained atopic dermatitis (AD) control on dupilumab.
Sponsor: Johns Hopkins University
You may qualify if…
- ✓ Aged 1 to \<18 years old, either sex, any race or ethnicity
- ✓ Provide signed informed consent by parent or legal guardian and informed assent if applicable
- ✓ Has a physician confirmed diagnosis of atopic dermatitis
- ✓ Has received dupilumab for at least 12 months for the treatment of atopic dermatitis
- ✓ Has had well-controlled atopic dermatitis on dupilumab within last 6 months (defined as POEM\<=7, EASI\<=7, or IGA\<=2)
- ✓ Able to speak English
- ✓ Able and willing to adhere to all study procedures
You may not qualify if…
- ✕ Taking concurrent systemic medication for atopic dermatitis (e.g., methotrexate, cyclosporine, tralokinumab, abrocitinib, upadacitinib, systemic corticosteroids)
- ✕ Using concurrent phototherapy for atopic dermatitis
- ✕ Taking dupilumab for a clinical indication other than atopic dermatitis (such as asthma or eosinophilic esophagitis)
- ✕ Poor control of atopic dermatitis
- ✕ Poor control of asthma or eosinophilic esophagitis
- ✕ Has used an investigational drug within 90 days or plan to use an investigational drug during the study period
- ✕ Does not have health insurance or will lose health insurance during the study period
Where it's recruiting
Maryland
Baltimore
Source: ClinicalTrials.gov · NCT06116526 · last updated 2026-04-20